Human leukemic cell lines synthesize hyaluronan to avoid senescence and resist chemotherapy

Glycobiology

Volumn 23, Issue 12, 2013, Pages 1463-1476

  Lompardía, Silvina Laura ^a   Papademetrio, Daniela Laura ^a   Mascaró, Marilina ^a   Del Carmen Álvarez, Elida María ^a   Hajos, Silvia Elvira ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

CD44; Drug resistance; Hyaluronan; Leukemia; RHAMM; Senescence

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; HYMECROMONE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CARBOHYDRATE SYNTHESIS; CELL MOTILITY; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL AGING; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; K562 CELL LINE; LEUKEMIA; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

CELL AGING; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; HYALURONIC ACID; HYMECROMONE; K562 CELLS; LEUKEMIA; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 84887923318     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwt074     Document Type: Article

References (46)

1. Arai E, Nishida Y, Wasa J., Urakawa H, Zhuo L, Kimata K., Kozawa E, Futamura N, Ishiguro N. 2011. Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer. 105:1839-1849.
2. Auvinen P, Tammi R, Kosma V., Sironen R, Soini Y, Mannermaa A., Tumelius R, Uljas E, Tammi M. 2013. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer. 132:531-539.
3. Baumgartner G, Gomar-Höss C, Sakr L, Ulsperger E, Wogritsch C. 1998. The impact of extracellular matrix on the chemoresistance of solid tumors-experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 131:85-99.
4. Bissell MJ, Radisky D. 2001. Putting tumours in context. Nat Rev Cancer. 1:46-54.
5. Boregowda RK, Appaiah HN, Siddaiah M, Kumarswamy S.B., Sunila S., Thimmaiah NK, Mortha K, Toole B, Banerjee S. 2006. Expression of hyalur-onan in human tumor progression. J Carcinog. 5:2.
6. Bourguignon LY, Peyrollier K, Xia W., Gilad E. 2008. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 283:17635-17651.
7. Bubnoff Nv, Duyster J. 2010. Chronic myelogenous leukemia. Treatment and monitoring. Dtsch Arztebl Int. 107:114-121.
8. Campisi J, d'Adda di Fagagna F. 2007. Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol. 8:729-740.
9. Cavaliere V, Papademetrio DL, Lorenzetti M, Valva P., Preciado MV, Gargallo P, Larripa I, Monreal M.B., Pardo ML, Hajos SE, et al 2009. Caffeic acid phe-nylethyl ester and MG-132 have apoptotic and antiproliferative effects on leukemic cells but not on normal mononuclear cells. Transl Oncol. 2:46-58.
10. Chang F, Lee JT, Navolanic P.M., Steelman LS, Shelton JG, Blalock WL, Franklin R.A., McCubrey JA 2003. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia. 17:590-603.
11. Cordo-Russo R.I., Alaniz LD, Saccodossi N, Lompardía S, Blanco G., Álvarez É, García MG, Hajos SE. 2010. Hyaluronan induces migration of multidrug-resistant lymphoma cell lines in vitro through Tiam1 activation by a PI3K-dependent mechanism. Leuk Res. 34:1525-1532.
12. Cordo Russo R.I., Ernst G, Lompardía S, Blanco G., Álvarez É, Garcia MG, Hajos S. 2012. Increased hyaluronan levels and decreased dendritic cell activation are associated with tumor invasion in murine lymphoma cell lines. Immunobiology. 217:842-850.
13. Cordo Russo R.I., García MG, Alaniz L., Blanco G, Alvarez E, Hajos SE 2008. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vin-cristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer. 122:1012-1018.
14. Croix BS, Man S, Kerbel R. 1998. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett. 131:35-44.
15. Csoka AB, Stern R. 2013. Hypotheses on the evolution of hyaluronan: A highly ironic acid. Glycobiology. 23:398-411.
16. Cui X, Zhou S, Xu H., Zhao T, Liu A, Guo X., Wang F. 2009. Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells. Anticancer Drugs. 20:800-806.
17. Dai R, Chen R, Li H. 2009. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol. 34:1749-1757.
18. Darzynkiewicz Z, Balazs EA 2012. Genome integrity, stem cells and hyaluro-nan. AGING. 4:78-88.
19. Debacq-Chainiaux F., Erusalimsky JD, Campisi J, Toussaint O. 2009. Protocols to detect senescence-associated beta-galactosidase (SA-β-gal) activity, a bio-marker of senescent cells in culture and in vivo. Nat Protoc. 4:1798-1806.
20. Drullion C, Trégoat C, Lagarde V., Tan S, Gioia R, Priault M., Djavaheri-Mergny M, Brisson A, Auberger P., Mahon FX, et al 2012. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence. Cell Death Dis. 3:e373.
21. García M.G., Alanis L, Cordo Russo RI, Alvarez E, Hajos SE 2009. PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk Res. 33:288-296.
22. Goueffic Y, Guilluy C, Guerin P., Patra P, Pacaud P, Loirand G. 2006. Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res. 72:339-348.
23. Greiner J, Schmitt M, Li L., Giannopoulos K, Bosch K, Schmitt A., Dohner K, Schlenk RF, Pollack J.R., Dohner H., et al 2006. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood. 108:4109-4117.
24. Itano N, Zhuo L, Kimata K. 2008. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci. 99:1720-1725.
25. Jiang D, Liang J, Noble PW 2011. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 91:221-264.
26. Johnson P, Ruffell B. 2009. CD44 And its role in inflammation and inflammatory diseases. Inflamm Allergy Drug Targets. 8:208-220.
27. Lokeshwar VB, Lopez LE, Munoz D, Chi A., Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N, Altman N. 2010. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 70:2613-2623.
28. Maxwell CA, McCarthy J, Turley E. 2008. Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions? J Cell Sci. 121:925-932.
29. McCubrey J, Steelman L, Chappell W., Abrams S, Wong E, Chang F., Lehmann B, Terrian D, Milella M., Tafuri A, et al 2007. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochem Biophys Acta. 1773:1263-1284.
30. Naor D, Wallach-Dayan SB, Zahalka M.A., Sionov RV 2008. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol. 18:260-267.
31. Nowell P, Hungerford D. 1960. A minute chromosome in human chronic gran-ulocytic leukemia. Science. 132:1497-1501.
32. Piccioni F, Malvicini M, Garcia M.G., Rodriguez A., Atorrasagasti C, Kippes N, Piedra Buena IT, Rizzo MM, Bayo J, Aquino J, et al 2011. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology. 22:400-410.
33. Provenzano PP, Hingorani SR 2013. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 108:1-8.
34. Rodier F, Campisi J. 2011. Four faces of cellular senescence. J Cell Biol. 192:547-556.
35. Rosen D, Harrington K, Cordeiro J., Leung L, Putta S, Lacayo N., Laszlo G, Gudgeon C, Hogge D., Hawtin R, et al 2013. AKT Signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One. 8:e53518.
36. Rowley JD. 1973. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 243:290-293.
37. Schmitt A, Barth TFE, Beyer E, Borchert F., Rojewski M, Chen J, Guillaume P., Gronau S, Greiner J, Moller P., et al 2009. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ Tcell responses. Int J Oncol. 34:10.
38. Slomiany MG, Dai L, Bomar P.A., Knackstedt TJ, Kranc DA, Tolliver L, Maria B.L., Toole BP 2009. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res. 69:4992-4998.
39. Telmer PG, Tolg C, McCarthy J.B., Turley EA 2011. How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression? Commun Integr Biol. 4:182.
40. Toole BP. 2004. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer. 4:528-539.
41. Toole BP. 2009. Hyaluronan-CD44 interactions in cancer: Paradoxes and possibilities. Clin Cancer Res. 15:7462-7468.
42. Twarock S, Freudenberger T, Poscher E., Dai G, Jannasch K, Dullin C., Alves F, Prenzel K, Knoefel W.T., Stoecklein NH, et al 2011. Inhibition of oesopha-geal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis. Mol Cancer. 10:30.
43. Urakawa H, Nishida Y, Wasa J., Arai E, Zhuo L, Kimata K., Kozawa E, Futamura N, Ishiguro N. 2012. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer. 130:454-466.
44. Wang SJ, Bourguignon LYW. 2011. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresis-tance. Am J Pathol. 178:956-963.
45. Yang L, Guo W, Zhang Q., Li H, Liu X, Yang Y., Zuo J, Liu W. 2011. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conform-ational change by Grp75 under glucose deprivation conditions. J Mol Biol. 414:654-666.
46. Yang M-Y, Lin P-M, Liu Y-C, Hsiao H-H, Yang W-C, Hsu J-F, Hsu C-M, Lin S-F. 2012. Induction of cellular senescence by doxorubicin Is associated with upregulated miR-375 and induction of autophagy in K562 cells. PLoS One. 7:e37205.